The Health Resources and Services Administration today delayed to May 22 the effective date of its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers, and invited comments on whether a delay to Oct. 1 would be more appropriate. The rule was set to take effect March 21 following an earlier two-week delay. “[The Department of Health and Human Services] believes that the delay of the effective date is necessary to consider questions of fact, law and policy raised in the rule, consistent with the ‘Regulatory Freeze Pending Review’ memorandum,” the notice states. “In addition, HHS believes that the delay of the effective date is necessary to provide regulated entities sufficient time to implement the requirements of the rule.” HRSA will accept comments through April 17.

Related News Articles

Headline
The Centers for Medicare & Medicaid Aug. 15 announced it negotiated lower prices with drug makers for 10 high-cost, sole-source drugs, with the new prices…
Headline
The AHA, joined by five other national hospital associations, Aug. 14 filed an amicus brief urging the Supreme Court to correct the Department of Health and…
Headline
The AHA Aug. 13 commented to the Medicare Payment Advisory Commission in anticipation of the commission’s 2024-2025 cycle. The AHA urged MedPAC to carefully…
Headline
More than 46 million prior authorization requests were submitted to Medicare Advantage insurers in 2022, according to KFF analysis released Aug. 6 examining…
Headline
The AHA along with the Federation of American Hospitals, America’s Essential Hospitals and the Association of American Medical Colleges July 29 filed an amicus…
Headline
The AHA July 26 submitted a letter expressing concerns in response to the recently introduced 340B Affording Care for Communities and Ensuring a Strong Safety-…